Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Oncogenic activated RAS mutations have been detected in 50% of de novo and 70% of relapsed multiple myeloma (MM) patients. Translocation t(11;14) involving IgH/CCDN1 and overexpression of cyclin-Ds are early events in MM pathogenesis, enhancing uncontrolled MM cell growth. We hypothesized that targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marisa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M., Hideshima, Teru, Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979823/
https://www.ncbi.nlm.nih.gov/pubmed/35082402
http://dx.doi.org/10.1038/s41375-021-01475-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979823/
https://www.ncbi.nlm.nih.gov/pubmed/35082402
http://dx.doi.org/10.1038/s41375-021-01475-z

Ejemplares similares